Shefali Agarwal, See Remarks at Epizyme, Inc. (EPZM), sold 1,780 shares at $2.93 ($5K) on 2021-12-06, disclosed to the SEC on 2021-12-07.
Scheduled sale ($5k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| EPZM | SELL | 2022-02-09 | $2K | — | Filing → |
| EPZM | SELL | 2022-02-04 | $4K | — | Filing → |
| EPZM | SELL | 2022-01-28 | $6K | — | Filing → |